 |
|
Now available in bulk from Ford-Speranza Nutraceuticals
|
Ecklonia Cava Extract
We guarantee it's purity to be more than 98%
As a Worldwide Retailer, Wholesaler, Distributer
We are able to give you the highest quality Ecklonia Cava Possible
Laboratory specs available upon request
VISIT OUR ONLINE STORE AND FOR WHOLESALE INFORMATION CONTACT US
The Superior Polyphenol Antioxidant
Many Times Stronger Than Green Tea Extract
Ecklonia Cava Extract: Polyphenol / Phlorotannin Derived from Brown Algae
Ecklonia Cava Extract known as (ECE) is a standardized organic complex of unique aquatic molecules that come from a specific species of brown algae (Ecklonia cava). Polyphenols are a group of chemical compounds found in plants, recognized by the presence of more than one phenol cluster per molecule. ECE represents a unique category of polyphenols normally called phlorotannins. Their unique polyphenolic structure endows them with biological activities which are not found in ground-based plants. Various physiological activities have been evaluated in both the individual compounds that we find in ECE and in the more complex forms through in vitro, in vivo and clinical studies.
Millions on Research
Dr. Haengwoo Lee and his team have spent over 32 million dollars on research, from in vitro to animal and human studies. Much of the work has been done in Korea, and some was done at the University of Washington. Ecklonia cava has been found to be a very impressive therapeutic supplement for a wide variety of health conditions.
THE SUPER ANTIOXIDANT
The potency of an antioxidant is often determined by its molecular structure, which is made up of rings. These rings provide the antioxidant function. Most flavonoids generally have three connected rings. ECE has up to eight interconnected rings, making its free-radical scavenging ability 10-100 times more powerful than other polyphenols. It is considerably stronger than green tea catechins.
Variable Antioxidant Profiles of ECE
Ecklonia Cava’s strength against various free radicals is known to be highly potent. ECE itself and its individual components have demonstrated potent reducing power and scavenging activities against free radicals such as oxidized LDL ("bad" cholesterol) and peroxynitrite (a powerful free radical that appears to play a major role in many disease processes).
A Longer Half-Life
ECE is a distinctive polyphenol in that it has a very long half-life (remains in the body longer). This is because ECE is a ocean-based polyphenol that is 40% fat-soluble. practically all other polyphenols are derived from land-based plants and are water-soluble. The half-life of ECE is up to 12 hours, compared to 30 minutes for water-soluble, land-based polyphenols. Because it is fat-soluble, ECE also has the ability to cross the blood-brain barrier.
The Research of Martin Pall, Ph.D.
Peroxynitrite is the most notorious of the free radicals incriminated by Martin Pall, Ph.D.'s groundbreaking research on multiple chemical sensitivity, fibromyalgia, chronic fatigue syndrome, post traumatic stress disorder, Gulf War syndrome, and fourteen other conditions. Peroxynitrite plays a main role in Dr. Pall’s mechanism, along with NF-kappaB (an important inflammatory mediator). ECE has been found to reduce NF-kappaB as well.
CARDIOVASCULAR BENEFITS
Coronary Artery Disease
Ecklonia Cava’s has been shown to improve coronary artery disease (CAD). Researchers found that ECE is even more effective at inhibiting the oxidation of LDL cholesterol ("bad" cholesterol) than green tea catechins, and appears to scrub the plaque off the endothelial lining. ECE also reduces vascular inflammation by preventing oxidation, which also directly effects the body's inflammatory response.
Coronary Artery Disease: 6-Week Clinical Trial
A clinical trial using ECE was conducted confirming its capacity to regenerate the vascular endothelium (the cells critical to the inner lining of the blood vessels) and recover plasticity of blood vessels after 6 weeks of treatment. The results indicate ECE's remarkable ability to induce recovery of endothelial cells and improve vascular plasticity. These findings demonstrate ECE’s ability to support restoration of vascular integrity by reversing atherosclerosis.
Cholesterol: 6-Week Clinical Trial
Researchers gave 39 adults (average age 55.6) low dose (100 mg) ECE compounds for six weeks. Their average cholesterol dropped from 228 to 224. LDL dropped from 141 to 135. HDL rose from 46.5 to 50.7 (highly significant). Triglycerides fell from 215 to 195, and the atherogenic index dropped 12.5%.
Some of the parameters from the above study show very moderate changes, which in themselves, may not be statistically significant. However, all parameters went in a health-positive direction, so taken together, the changes in LDL, HDL, triglycerides, blood pressure, and antioxidant protection are very significant. Also, endothelial cells were protected against oxidative damage, and were able to produce significantly more nitric oxide, which dilates blood vessels. Dramatic increases in blood flow were also found at this low dose.
High Blood Pressure: 4-Week Animal Study
The extraordinary effect of ECE on vasodilation was clearly confirmed in a study of rats with induced high blood pressure. Upon oral administration of ECE phlorotannin (50 mg/kg) or enalapril (a commercial drug for high blood pressure 10 mg/kg), blood pressure dropped to as low as 160 and 140 mm Hg. Upon termination of treatment, blood pressure increased again in both cases. even though ECE showed a similar pattern to the drug, it also showed a slower rebounding of blood pressure during the no treatment period, which indicates its potential as a vascular protector with prolonged oral administration.
ACE Inhibition
ECE tannins have been found to be powerful natural ACE inhibitors, demonstrating more than 15 times the power to inhibit ACE as the most powerful land-based polyphenols, as well as the natural hypotensive substance catechin found in green tea.
As well, one of the compounds found in ECE (THP-BE) is equivalent to bradykinin, an significant hormone produced by the body that helps keep blood vessels dilated and open, thus encouraging healthy blood flow and blood pressure.
Antiplasmin Inhibition
Plasmin (an important fibrinolytic enzyme that breaks down blood clots) is quickly blocked by a protein called antiplasmin. ECE compounds are natural potent inhibitors of anti-plasmin, capable of efficient promotion of plasmin that performs fibrinolysis. ECE compounds have shown amazing activity which is 40-200 times greater than the anti-plasmin inhibiting drugs Flufenamate and Chloramine T.
ERECTILE FUNCTION ECE V. VIAGRA®
Nitric Oxide
As discussed earlier, Ecklonia Cava can rejuvenate the vascular endothelium. They produce the chemical nitric oxide (NO), that keeps the arterial walls relaxed and dilated. After a 6 -week study of ECE, flow mediated dilation and NO mediated dilation increased by 60% and 50%. In another study, coronary artery disease patients were given ECE for six weeks. Blood flow controlled by NO increased 50-60%. These results confirm that ECE can rejuvenate damaged endothelial cells to produce NO. This effect was further confirmed in a study on erectile dysfunction (see below). Interestingly, Viagra® works by increasing NO in the penile artery.
ECE v.Viagra®: 8-Week Clinical Trial
Scientists studied 31 men with erectile dysfunction for over six months. For eight weeks they compared ECE to Viagra®. They looked at orgasmic function, intercourse fulfillment, erectile function, and overall fulfillment. No side effects were reported with Ecklonia Cava Extract.
During the course of 8 weeks ECE & Viagra® scored:
ECE scored: Orgasmic Function: 87%
Erectile Function: 66%
Intercourse Satisfaction: 74%,
Overall Satisfaction: 62%
Viagra® scored: Orgasmic Function: 27%
Erectile Function: 66%
Intercourse Satisfaction: 44%,
Overall Satisfaction: 39%
In addition, scores on key questions (frequency of penetration and frequency of maintaining an erection after penetration), which directly indicate the ability to attain and maintain an erection adequate for sexual activity and penitration, were improved by 74% and 77%.
The results powerfully indicate that the long-term oral consumption of ECE drastically contributes to the normalization of the general vascular environment around the sexual organ. The mechanism of which is most likely due to neutralization of oxidative risk factors, thus improving peripheral blood circulation around muscles and nerves involved in sexual function as well as the penile artery.
Long-Term Improvement Possibilities
When taking all of ECE's benefits into consideration, long-term oral administration of ECE may contribute to long-term improvement in vascular health, including the penile artery.
FIBROMYALGIA
ECE: Phase I Clinical Trial Preliminary Results
In a 2 month, double-blinded study of recognized fibromyalgia patients, ECE was administerd as an additional therapy to the patients’ current standard of Doctor care. The results established the general safety of ECE. ECE cut the time it took the participants to fall asleep by 47 minutes; it augmented total nighttime sleep by 1.6 hours; it improved depth of sleep by 80%; it boosted their energy levels by70%; it gave them 2 1/4 more good days per week; it helped decrease their pain by 30%; and their general condition improved by 40%. Interestingly, these improvements were achieved at all doses. Patients given the placebo had no improvement during the study.
ECE & FIBROMYALGIA
BRAIN FUNCTION: MEMORY, RELAXATION, ALERTNESS
Greatly Improved Blood Flow
Since Ecklonia Cava is fat-soluble, it has the capability to cross the blood-brain barrier and considerably improves blood flow to the brain. This is another way ECE improves memory. More specifically, Dr. Lee’s group found that ECE increases the rate of blood flow in the carotid artery (the main artery to the brain) from an average of 36.68 cm/ sec. to 40.09 cm/sec., while the placebo had no improvement.
Memory & Acetylcholine
Memory is related to the neurotransmitter acetylcholine (ACh). In an animal study, ECE increased rodent acetylcholine by 140% in the brain regions responsible for learning and memory in just 7 days. Memory augmentation increased by 100-200% at a dose as low as 0.2-1mg/kg.
Regard to mechanism, it is contemplation that ECE works by slightly inhibiting an enzyme that breaks down acetylcholine called acetylcholinesterase. By inhibiting this enzyme, the availability and utilization of acetylcholine in the body would be enhanced.
Alertness
Another study establish that ECE compounds prevented sleepiness in bus drivers and in high school students for the duration of daytime activities. This is also probable due to increased blood flow and oxygen delivery to the brain.
Relaxation & Alpha-Waves
An EEG study on brain waves of healthy middle age volunteers found that ECE compounds increase alpha-waves. Alpha-waves are an indicator of relaxation.
Neuroprotective Effects
Ecklonia Cava has demonstrated potent neuroprotective effects due to several features of its components. ECE compounds are both powerful antioxidants and anti-inflammatory compounds capable of scavenging free radicals and suppressing excessive inflammatory reactions. Fucoidan, an ECE compound, has been found to protect neuronal cells from ischemia-induced (reduced blood flow) inflammatory reactions which often occur in the aged and highly stressed brain. ECE compounds also deactivate the powerful neurotoxic free-radical peroxynitrite.
Resistance of Stress-Induced Learning Deficit in Mice
In a 5-day study, Ecklonia Cava treated mice showed considerable resistance to electric shock treatment-induced learning deficit, as compared to non-treated mice whose learning process was considerably retarded during the test period.
Enhanced Memory in Mice
The positive effects of ECE compounds on memory augmentation were further demonstrated by measuring the latency time avoiding the previously experienced electric shock treatment in mice as passive-avoidance memory testing. After 7 days oral administration of two ECE compounds DE and PFF
Enhancement of Acetylcholine Levels in Mice
With 7 days of oral administration of two Ecklonia Cava compounds (DE 10 mg/kg and PFF 2 mg/kg), mice under ethanol-induced cognitive impairment showed substantial enhancement of acetylcholine levels in three brain regions related to memory formation, as compared with non-treated mice. Acetylcholine was enhanced by 140% in the frontal cortex, the part of the brain crucial for long-term memory and associative thinking.
(as low as 1 and 0.2 mg/kg), mice under ethanol-induced cognitive impairment showed 130-140% improvement, especially in the PFF group.
Beta-Amyloid Deposition Inhibition in Rats
Researchers at the National Institute of Health’s aging research labs in Baltimore studied ECE in rats, and found it to inhibit beta-amyloid deposition in the brain. Beta-amyloid is the substance that accumulates in Alzheimer’s disease. The rats also learned maze challenges faster, which demonstrated improvement in short-term memory.
ARTHRITIS, INFLAMMATION, NEURALGIA
Dr. Lee and colleagues found Ecklonia Cava to naturally suppress inflammatory responses and defuse inflammatory damage caused by free radicals. The most favorable combination of ECE’s natural anti-inflammatory and tissue-protective properties appears to enable remarkable improvement in both arthritis and neuralgia. with human trial, ECE considerably reduced pain in a group of knee arthritis patients compared to placebo.
Cartilage protecting properties
Ecklonia Cava Extract compared nearly identically to celecoxib in the ability to reduce PGE2 by slowing down the lipoxygenase (LOX) system (a key inflammatory enzyme system). ECE compounds have more than double the ability of resveratrol (a powerful antioxidant polyphenol found in red grapes) to inhibit LOX. These results were demonstrated in a study on rabbit cartilage cells. Those cells treated with ECE had up to an 80% reduction in degeneration.
Comparable to Celebrex®
Ecklonia Cava’s ability to treat arthritis has been found to be comparable to Celebrex®, the prescription drug that reduces inflammatory enzymes known as "COX" enzymes.
The influence of ECE on the generation of inflammatory prostaglandins known as PGE2 was studied. ECE, celecoxib (Celebrex®) and aspirin all showed considerable inhibition of PGE2 generation in the concentration range tested. More exclusively, ECE showed inhibition of 61%, 85%, 92% and 99% at concentrations of 10, 30, 60 and 100 µg/mL correspondingly, showing similar activity to celecoxib which showed 65%, 79%, 85% and 96%.
Conjecture about Neuropathy Mechanism
The strong lipid and cholesterol reducing potential of ECE supports reduced vascular inflammation. Increasingly, the scientific literature supports the notion that many forms of nerve pain or neuropathy are caused by nerve pressure, as exerted by swollen, inflamed blood vessels adjacent to the nerves.
Neuropathy: 4-Week Clinical Trial
Researchers recently studied ECE on 40 patients with neuropathy. ECE reduced nerve pain by 40% in four weeks. Overall, 80% of the patients responded favorably.
ALLERGIES / ASTHMA
ECE appears to significantly relieve allergic reactions without drowsiness, dizziness and other side effects of anti-histamine drugs.
University of Washington Asthma Mouse Study
The efficiency of ECE for asthma was confirmed in an allergen-induced murine asthma mouse study by Dr.
Emil Chi, Chairman, Histopathology Department, Washington University.
The researchers tested an Ecklonia Cava Extract product (KLS) in a mouse study of allergen-induced chronic lung inflammation and fibrosis. The antigen-treated mice developed an extensive cellular inflammatory reaction, overproduction of mucus and airway mucus plugging.
KLS was found to be effective in considerably reducing allergic reaction in inflammation. KLS reduced airway mucus plugging, and sub-epithelial fibrosis in the antigen-sensitized challenged mice. KLS were shown to be successful in improving the asthmatic lung structures. No pathological alterations in the liver, kidney, spleen, or small intestine were found.
Allergic Inflammation: Mouse Study
Dr. Lee and his team found that ECE significantly reduced allergic inflammation in mice. Specifically, ECE reduced the migration of eosinophils (inflammatory white blood cells) to the lungs by 75%. Eosinophils and resulting cytokines were reduced by 50%. Mucus plugs in the airways were reduced by 75%. Airway epithelial hyperplasia reduced by 75%. Collagen-causing fibrosis in lung interstitium (fibrosis, airway remodeling) and smooth muscle cell thickness was reduced by 20% and 32%. These latter findings suggest that ECE compounds may prevent or reverse the progression of chronic lung disease such as asthma and Chronic Obstructive Pulmonary Disease (COPD).
5-Lipoxygenase (5-LOX)
Because the 5-LOX system plays such a major role in inflammatory and allergic responses, inhibition of 5-LOX has become a medicinal target for the treatment of inflammatory diseases. One of the ECE compounds (8,8-BE) significantly inhibits 5-LOX compared with other well-known natural medicinal compounds such as resveratrol and EGCG. |
WEIGHT LOSS
Ecklonia Cava Extract Beverage: 2-Week Clinical Trial
With a human study, 141 young adults were given a beverage containing ECE at 200 mg daily. In two weeks their regular weight dropped nearly 2.5 pounds, muscle mass increased by nearly 2.5 pounds, and body fat dropped by 4 pounds, or 7.48%. ECE stimulates the body to burn fat by increasing muscle mass.
DGAT Inhibition
The Diacylglycerol acetyl transferase (DGAT) is an vital enzyme involved in triglyceride synthesis. Triglycerides are circulating fat molecules that ultimately wind up in the fat cells, and are almost always elevated in diabetes. They also have emerged as a major risk factor for vascular diseases.
Dr. Lee found that ECE compounds inhibited DGAT more than 50%. In genetically caused obese laboratory rats, ECE reduced body fat and increased physical activity. In another study, ECE caused leanness and fat-resistance in animals given a high fat diet.
OBESITY
Cardiovascular Protection
Obviously, Ecklonia Cava Extract’s many health benefits provide additional cardiovascular protection for obese and morbidly patients, who are more prone to cardiovascular and coronary heart disease. As discussed, ECE lowers LDL cholesterol, suppresses triglyceride fabrication, promotes healthy blood flow, lowers blood pressure, and scavenges free radicals, to name a few.
DGAT Inhibition & Obesity
DGAT inhibition has recently been recognized as a novel and safe target for the treatment of obesity. DGAT (diacylglycerol acyltransferase) is a key enzyme involved in intestinal fat absorption, triglyceride levels, fat storage, and energy metabolism in muscles. In a mouse study in which DGAT was inhibited, mice demonstrated obesity resistance with a high-fat diet. ECE compounds are found to inhibit DGAT.
|
DIABETES
Reduced Fat in Liver & Pancreas
A mouse study showed that ECE reversed fat deposition in liver and pancreas cells. in addition, this same study showed that ECE served to markedly inhibit inflammation in the pancreas. A recent Harvard (Joslin School of Diabetes) mouse study directly implicates excessive fat deposition in the mouse pancreas for turning on the inflammation pathway, resulting in full-blown type II diabetes and insulin insensitivity in the mice.
Aldose Reductase Inhibition
When blood sugar’s become elevated, the enzyme aldose reductase converts surplus glucose into the sugar alcohol sorbitol. Sorbitol can build in critical cells and cause damage. Recent research found that animals lacking in aldose reductase were protected from the retinal complications of diabetes. ECE compounds have been found to be potent aldose reductase inhibitors, which may be of benefit for patients with metabolic syndrome, syndrome X, or diabetes.
SAFETY
Ecklonia Cava Extract is contrived from edible algae through food-compatible processes. Hundreds of thousands of people all through the world have experienced ECE in a variety of forms with no side effects. To date, Dr. Lee’s team has not found any toxicity at any level. numerous toxicity tests have been performed, and no adverse side effects have been found at the effective human dose level of 1-10 mg/kg.
References
- “Compound
For Improving Hypertension Containing Inhibitors Of Angiotensin
Converting Enzyme Activity Extracted From Marin Plants And Articles
Comprising Thereof”, Korean Patent Application 10-2004-24347 (Livechem,
Inc).
- “Composition
For Prevention And Improvement Of Dementia And Promotion Of Memory, And
Healthy Assistance Foodstuffs Containing The Composition” Korean Patent
Application# 10-2003-88177 (Assigned To Haengwoo Lee).
- Ahn MJ, Yoon KD,
Min SY, Lee JS, Kim JH, Kim TG, Kim SH, Kim NG, Huh H, Kim J.
Inhibition of HIV-1 reverse transcriptase and protease by phlorotannins
from the brown alga Ecklonia cava. Biol Pharm Bull. 2004
Apr;27(4):544-7.
- Aikawa, T., S. Shimura, H.
Sasaki, M. Ebina, And T. Takishima. 1992. Marked Goblet
Cell Hyperplasia With Mucus Accumulation In The Airways Of Patients Who
Died Of Severe Acute Asthma Attack. Chest 101:916-921.
- Athukorala
Y, Kim KN, Jeon YJ. Antiproliferative and antioxidant properties of an
enzymatic hydrolysate from brown alga, Ecklonia cava. Food Chem
Toxicol. 2006 Jul;44(7):1065-74. Epub 2006 Mar 3.
- Becker
AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U, Jonas U.
Plasma levels of angiotensin II during different penile conditions in
the cavernous and systemic blood of healthy men and patients with
erectile dysfunction. Urology. 2001 Nov;58(5):805-10.
- Becker
AJ, Uckert S, Stief CG, Truss MC, Machtens S, Scheller F, Knapp WH,
Hartmann U, Jonas U. Possible role of bradykinin and angiotensin II in
the regulation of penile erection and detumescence. Urology. 2001
Jan;57(1):193-8.
- De
Angelis L, Marfella MA, Siniscalchi M, Marino L, Nappo F, Giugliano F,
De Lucia D, Giugliano D. Erectile and endothelial dysfunction in Type
II diabetes: a possible link. Diabetologia. 2001 Sep;44(9):1155-60.
- Cases S, Smith SJ, Zheng
YW, Myers HM, Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusis AJ,
Erickson SK, Farese RV Jr. Identification of a gene encoding an acyl
CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol
synthesis. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13018-23.
- Chapman VJ, Chapman DJ. (1980). Seaweeds and their uses. London: Chapman & Hall.
- “Compound For Improving Neuralgia
Containing Dibenzo-P-Dioxine Derivatives Extracted From Marine Plants
And Articles Comprising Thereof”. Korean Patent Application
10-2004-0028066 (Livechem, Inc).
- Djukanovic,
R., J.W. Wilson, K.M. Britten, S.J. Wilson, A.F. Walls, W.R. Roche,
P.H. Howarth, S.T. Holgate. 1990. Quantitation Of Mast
Cells And Eosinophils In The Bronchial Mucosal Of Symptomatic Atopic
Asthmatics And Healthy Control Subjects Using
Immunohistochemistry. Am.Rev.Respir.Dis. 142:863-871.
- Fukuyama
Y, Kodama M, Miura I, Kinzyo Z, Mori H, Nakayama Y, Takahashi M.
Anti-plasmin inhibitor. VI. Structure of phlorofucofuroeckol A, a novel
phlorotannin with both dibenzo-1,4-dioxin and dibenzofuran elements,
from Ecklonia kurome Okamura. Chem Pharm Bull (Tokyo). 1990
Jan;38(1):133-5.
- Fukuyama,
Y., Kodama, M., Miura, I., Kinzyo, Z., Kido, M., Mori, H., Nakayama,
Y., Takahashi, M. Structure Of An Anti-Plasmin Inhibitor, Eckol,
Isolated From The Brown Alga Ecklonia Kurome Okamura And Inhibitory
Activities Of Its Derivatives On Plasmin Inhibitors. Chem. Pharm. Bull.
37: 349-353 (1989)
- Glombitza, K.W., Gerstberger,
G. Phlorotannins With Dibenzodioxin Structural Elements From The Brown
Alga Eisenia Arborea. Phytochemistry 24: 543-551 (1985)
- Dorrance
AM, Lewis RW, Mills TM. “Captopril Treatment Reverses Erectile
Dysfunction In Male Stroke Prone Spontaneously Hypertensive
Rats.” Int J Impot Res. 2002 Dec;14(6):494-7
- Hamed EA, Meki AR, Gaafar
AA, Hamed SA. Role Of Some Vasoactive Mediators In Patients With
Erectile Dysfunction: Their Relationship With Angiotensin-Converting
Enzyme And Growth Hormone. Int J Impot Res. 2003
Dec;15(6):418-25.
- Henderson,
W.R., Jr., D.B. Lewis, R.K. Albert, Y. Zhang, W.J.E. Lamm, G.K.S.
Chiang, F. Jones, P. Eriksen, Y. Tien, M. Jonas, E.Y. Chi.
1996. The Importance Of Leukotrienes In Airway Inflammation In A
Mouse Model Of Asthma. J. Exp. Med. 184:1483-1494.
- Henderson,
W.R., Jr., E.Y. Chi, C.R. Maliszewski. 2000. Soluble
Interleukin-4 Receptor (Sil-4R) Inhibits Airway Inflammation Following
Allergen Challenge In A Mouse Model Of Asthma. J. Immunol.
164:1086-1095.
- Grunig
G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard
D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. Requirement for IL-13
independently of IL-4 in experimental asthma. Science. 1998 Dec
18;282(5397):2261-3.
- Henderson, W.R., E.Y.
Chi. 1985. Ultrastructural Characterization And Morphometric
Analysis Of Human Eosinophil Degranulation. J. Cell Sci. 73:33-48.
- Hoppe HA. (1979). Marine algae and
their products and constituents in pharmacy. In: Marine Algae in
Pharmaceutical Science. Hoppe HA, Levring T, Tanaka Y, eds. Berlin
& New York: Walter de Gruyter.
- Hoshino, M.,
Y. Nakamura, J.J. Sim. 1998. Expression Of Growth Factors
And Remodeling Of The Airway Wall In Bronchial Asthma. Thorax
53:21-27.
- Kang K, Park Y, Hwang HJ, Kim SH, Lee
JG, Shin HC. Antioxidative properties of brown algae polyphenolics and
their perspectives as chemopreventive agents against vascular risk
factors. Arch Pharm Res. 2003 Apr;26(4):286-93.
- Kang KA, Lee KH, Chae
S, Zhang R, Jung MS, Ham YM, Baik JS, Lee NH, Hyun JW. Cytoprotective
effect of phloroglucinol on oxidative stress induced cell damage via
catalase activation. J Cell Biochem. 2006 Feb 15;97(3):609-20.
- Kang
KA, Lee KH, Chae S, Zhang R, Jung MS, Lee Y, Kim SY, Kim HS, Joo HG,
Park JW, Ham YM, Lee NH, Hyun JW. Eckol isolated from Ecklonia cava
attenuates oxidative stress induced cell damage in lung fibroblast
cells. FEBS Lett. 2005 Nov 21;579(28):6295-304. Epub 2005 Oct 19.
- Kang,
K., Park, Y., Hwang, H. J., Kim, S. H., Lee, J. G., Shin, H.-C. (2003).
Antioxidative Properties Of Brown Algae Polyphenolics And Their
Perspectives As Chemopreventive Agents Against Vascular Risk Factors.
Arch. Pharm. Res.. 26: 286-293
- Kang
KA, Lee KH, Chae S, Koh YS, Yoo BS, Kim JH, Ham YM, Baik JS, Lee NH,
Hyun JW. Triphlorethol-A from Ecklonia cava protects V79-4 lung
fibroblast against hydrogen peroxide induced cell damage. Free Radic
Res. 2005 Aug;39(8):883-92.
- Kang, K.J., Hwang,
H.J., Hong, D.H., Park, Y.J., Kim, S,H., Lee, B.H., Shin, H.C.
Anti-Oxidant And Anti-Inflammatory Activities Of Ventol, A
Phlorotannin-Rich Natural Agent Derived From Ecklonia Cava, And Its
Effect On Proteoglycan Degradation In Cartilage Explant Culture.
Submitted To Molecular Pathology And Pharmacology
- Kay, A.B. 1997. T Cells As Orchestrators Of The Asthmatic Response. Ciba Found. Symp. 206:56-67.
- Kim
MM, Ta QV, Mendis E, Rajapakse N, Jung WK, Byun HG, Jeon YJ, Kim SK.
Phlorotannins in Ecklonia cava extract inhibit matrix metalloproteinase
activity. Life Sci. 2006 Sep 5;79(15):1436-43. Epub 2006 May 7.
- Krug,
N., J. Madden, A.E. Redington, P. Lackie, R. Djukanovic, U. Schauer,
S.T. Holgate, A.J. Frew, P.H. Howarth. 1996. T-Cell
Cytokine Profile Evaluated At The Single Cell Level In Bal And Blood In
Allergic Asthma. Am. J. Respir. Cell Mol. Biol. 14:319-326.
- Lee,
B.H., Stein, S. Improvement Of Learning Behavior Of Mice By An
Antiacetylcholinesterase And Neuroprotective Agent Nx42, A
Laminariales-Alga Extract. Presented To The Pharm. Soc. Kor., Spring
Conference (2004); Manuscript Submitted To Korean Journal Of Food
Science And Technology.
- Lee, S.H., Han, S.B.,
Baik, J.Y. The Influence Of VNP Intake On The Symptoms Of
Osteoarthritis Of The Knee Joint. Clinical Report By Department
Of Orthopedic Surgery, Anam Hospital, Korea University Medical Center
- Kang
KA, Zhang R, Lee KH, Chae S, Kim BJ, Kwak YS, Park JW, Lee NH, Hyun JW.
Protective effect of triphlorethol-A from Ecklonia cava against
ionizing radiation in vitro. J Radiat Res (Tokyo). 2006 Mar;47(1):61-8.
- Mcever,
R.P. 1991. Selectins: Novel Receptors That Mediate
Leukocyte Adhesion During Inflammation. Thromb. Haemost.
65:223-228.
- Myung CS, Shin HC, Bao HY, Yeo SJ,
Lee BH, Kang JS. Improvement of memory by dieckol and
phlorofucofuroeckol in ethanol-treated mice: possible involvement of
the inhibition of acetylcholinesterase. Arch Pharm Res. 2005
Jun;28(6):691-8.
- Nakamura, T., Nagayama, K.,
Uchida, K., Tanaka, R. Antioxidant Activity Of Phlorotannins Isolated
From The Brown Alga Eisenia Bicyclis. Fisheries Sci. 62: 923-926 (1996).
- Roche,
W.R., R. Beasley, J.H. Williams, S.T. Holgate. 1989.
Subepithelial Fibrosis In The Bronchi Of Asthmatics. Lance
1:520-524.
- Ruehl ML, Orozco JA, Stoker MB,
Mcdonagh PF, Coull BM, Ritter LS. Protective Effects Of Inhibiting Both
Blood And Vascular Selectins After Stroke And Reperfusion. Neurol Res.
2002 Apr;24(3):226-32.
- Sheehan, D.C., B.B.
Hrapchak. 1980. Connective Tissue/Muscle Fiber Stains. In Theory
And Practice Of Histotechnology. Battelle Press, Columbus, OH.
180-201.
- Shibata, T., Nagayama, K., Tanaka,
R., Yamaguchi, K., Nakamura, T. Inhibitory Effects Of Brown Algal
Phlorotannins On Secretory Phospholipase A2S, Lipoxygenases And
Cycloxygenases. J. Appl. Phycol. 15: 61-66 (2003)
- Shin
HC, Hwang HJ, Kang KJ, Lee BH. An antioxidative and antiinflammatory
agent for potential treatment of osteoarthritis from Ecklonia cava.
Arch Pharm Res. 2006 Feb;29(2):165-71.
- Smith SJ,
Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel
RH, Farese RV Jr. Obesity resistance and multiple mechanisms of
triglyceride synthesis in mice lacking Dgat. Nat Genet. 2000
May;25(1):87-90.
- Shibata, T., Fujimoto, K., Nagayama, K.,
Yamaguchi, K., Nakamura, T. Inhibitory Activity Of Brown Algal
Phlorotannins Against Hyaluronidase. Int. J. Food Sci. Tech. 37:
703-709 (2002)
- Tsukada
H, Nishiyama S, Fukumoto D, Ohba H, Sato K, Kakiuchi T. Effects of
acute acetylcholinesterase inhibition on the cerebral cholinergic
neuronal system and cognitive function: Functional imaging of the
conscious monkey brain using animal PET in combination with
microdialysis. Synapse. 2004 Apr;52(1):1-10.
- Virag
R, Floresco J, Richard C. Impairment Of Shear-Stress-Mediated
Vasodilation Of Cavernous Arteries In Erectile Dysfunction. Int J
Impot Res. 2004 Jan;16(1):39-42
- Wills-Karp, M.,
J. Luyimbazi, X. Xu, B. Schofield, T.Y. Neben, C.L. Karp, D.D.
Donaldson. 1998. Interleukin-13: Central Mediator Of
Allergic Asthma. Science 282:2258-2261.
- Temann UA, Prasad B, Gallup MW,
Basbaum C, Ho SB, Flavell RA, Rankin JA. A novel role for murine IL-4
in vivo: induction of MUC5AC gene expression and mucin hypersecretion.
Am J Respir Cell Mol Biol. 1997 Apr;16(4):471-8.
- Zhu, Z.,
R.J. Homer, Z. Wang, Q. Chen, G.P. Geba, J. Wang, Y. Zhang, J.A.
Elias. 1999. Pulmonary Expression Of Interleukin-13 Causes
Inflammation, Mucus Hypersecretion, Subepithelial Fibrosis, Physiologic
Abnormalities, And Eotaxin Production. J. Clin. Invest.
103:779-78
- Uhm
CS, Kim KB, Lim JH, Pee DH, Kim YH, Kim H, Eun BL, Tockgo YC. Effective
treatment with fucoidin for perinatal hypoxic-ischemic encephalopathy
in rats. Neurosci Lett. 2003 Dec 15;353(1):21-4.
|
Tell A Friend About Us : Email This Page
|